Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Growth Rate of the Recombinant DNA Technology Market?

In recent times, the market size of recombinant DNA technology has experienced robust growth. The market is projected to expand from $858.94 billion in 2024 to $920.82 billion in 2025, showcasing a compound annual growth rate (CAGR) of 7.2%. This growth during the historical period can be credited to the increasing demands in healthcare, expansion of the biopharmaceutical industry, higher investments in research and development, and the advent of personalized medicine.

What Growth Rate Is Forecasted for the Recombinant DNA Technology Market by 2029?

In the coming years, the size of the recombinant DNA technology market is anticipated to experience significant growth, projecting to expand to a worth of $1318.72 billion by 2029 with a 9.4% compound annual growth rate (CAGR). This expected growth during the forecast period is linked to factors such as the rise in chronic diseases, the emergence of new biotech companies, heightened investment in biotech, broadening global biotech markets, as well as user acceptance and education. The forecast period is also expected to witness key trends such as scientific progress, developments in gene editing, cell and gene therapy, RNA therapeutics, rare disease therapeutic applications, and the integration of artificial intelligence and data.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8233&type=smp

Which Key Companies Are Shaping the Future of the Recombinant DNA Technology Market?

Major companies operating in the recombinant DNA technology market are Profacgen BioTech Corp., Amgen Inc., Novartis International AG, GenScript Biotech Corporation, Pfizer Inc., Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., Merck & Co. Inc., Biogen Inc., GlaxoSmithKline PLC, New England Biolabs Inc., Bayer CropScience, Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals Inc., Gilead Sciences Inc., Moderna Inc., Vertex Pharmaceuticals Incorporated, CRISPR Therapeutics AG, Editas Medicine Inc., bluebird bio Inc., Illumina Inc., Qiagen N.V., Lonza Group AG, Bio-Rad Laboratories Inc., Agilent Technologies Inc., Becton Dickinson and Company, Sartorius AG, Abcam PLC, Horizon Discovery Group PLC, Integrated DNA Technologies Inc., Twist Bioscience Corporation, Synthego Corporation, Codex DNA Inc., InvivoGen, Eurofins Scientific SE, Sarepta Therapeutics Inc., Sangamo Therapeutics Inc.

Which Factors Are Driving Demand in the Recombinant DNA Technology Industry?

The recombinant DNA technology market is predicted to expand due to a rise in chronic diseases. These diseases persist for a year or more, requiring ongoing medical care and often impacting daily activities. The development of recombinant DNA technology has revolutionized healthcare by producing biopharmaceutical proteins used in medicine and by introducing healthy genes in place of defective ones through gene therapy, aiming for a complete cure. For example, the World Health Organization, a Switzerland-based intergovernmental organization, forecasted in February 2024 that over 35 million new cancer cases would emerge by 2050, marking a 77% surge compared to the projected 20 million cases in 2022. As a result, the growing prevalence of chronic diseases is propelling the growth of the recombinant DNA technology market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=8233&type=smp

How Is the Recombinant DNA Technology Market Segmented by Several Divisions?

The recombinant DNA technology market covered in this report is segmented –

1) By Product Type: Recombinant Protein Drugs, Vaccines, Genetically Modified Crops, Expression Systems, Cell And Gene Therapy, Gene Editing

2) By Component Type: Expression System, Cloning Vector

3) By Application Type: Food And Agriculture, Health And Disease, Environment, Other Application Types

4) By End-Use Type: Biotechnology And Pharmaceutical Companies, Academic And Government Research Institutes, Other End-Use Types

Subsegments:

1) By Recombinant Protein Drugs: Hormones, Growth Factors

2) By Vaccines: Recombinant Viral Vaccines, Recombinant Bacterial Vaccines, Subunit Vaccines

3) By Genetically Modified Crops: Herbicide-Tolerant Crops, Insect-Resistant Crops, Nutritionally Enhanced Crop

4) By Expression Systems: Bacterial Expression Systems, Yeast Expression Systems, Mammalian Expression Systems

5) By Cell And Gene Therapy: Cell-Based Therapies, Gene Replacement Therapies, CAR T-Cell Therapies

6) By Gene Editing: CRISPR Or Cas9 Technologies, TALENs (Transcription Activator-Like Effector Nucleases), ZFNs (Zinc Finger Nucleases)

What are the Emerging Market Trends Driving the Growth of the Recombinant DNA Technology Industry?

The recombinant DNA technology market is characterized by substantial technological advancements. Many leading businesses in this market are investing in ground-breaking technologies to maintain their competitive edge. For instance, Bluebird bio, Inc., a biotechnology firm in the United States, launched the first FDA-approved gene therapy for beta-thalassemia, ZYNTEGLO, in August 2022. This one-time gene therapy targets the genetic cause of beta-thalassemia, possibly freeing patients from the need for ongoing red blood cell transfusions. By using an ex-vivo lentiviral vector to change patient cells, it represents a significant step forward in reducing the continuous management of beta-thalassemia.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/recombinant-dna-technology-global-market-report

Which Regions Are Driving Growth in the Recombinant DNA Technology Market?

North America was the largest region in the recombinant DNA technology market share in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the recombinant DNA technology market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8233

This Report Delivers Insight On:

1. How big is the recombinant dna technology market, and how is it changing globally?

2. Who are the major companies in the recombinant dna technology market, and how are they performing?

3. What are the key opportunities and risks in the recombinant dna technology market right now?

4. Which products or customer segments are growing the most in the recombinant dna technology market?

5. What factors are helping or slowing down the growth of the recombinant dna technology market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model